������������������
���������������������
�������������������������������
������ ����������
� ��������
��������� ������
The perfect Masterclass
FRIDAY, 19TH JUNE 2020 Scientific Program
07:30h Opening of registration desk
08:30-08:40h Opening lecture
08:40-09:10h Epidemiology and Etiology
• Natural history of PCa and it’s risk factors
• Biomarkers in prostate cancer: Any good news?
• Genomics, radiomics and racial disparities in PCa. Where do we stand?
• Molecular subtypes of PCa
• My father had it, what about me? Hereditary prostate cancer
• Doctor, what should I eat/drink? Gleason vs ISUP grades: Was it necessary?
09:10-09:30h Pathology in Pca in 2020: Update and new trends
09:30-09:45h Screening
• Improving specificity of PSA screening: Serum and urine markers
• USPTF: Why are there no urologists in the room?
• The harms of no screening
• Europe vs. the World (ERPCG vs. PLCO)
• I’m 45, can I get my PSA results, please?
• Before biopsy: What to do?
09:45-10:30h Diagnosis and Staging
• Biomarkers
• Liquid Biopsy
• Classic biopsy: Should we still do it? Fusion and systematic biopsy – The new standard?
• Targeted biopsy techniques and mpMRI-guided biopsy
• How to interpret multi-parametric MRI for improving diagnostic and therapeutic procedures
• MRI-targeted fusion biopsies: Are random biopsies still useful? Cognitive versus software-based fusion
• Do I really need a prostate biopsy?
• How long till my next biopsy?
• Patient tailored staging? Adequate?
• Which imaging method after initial prostate cancer diagnosis?
• Role of PSMA in PCa: A new standard? Primary. Recorrent
• PSMA – Diagnostic and therapeutic potential
10:30-11:00h Coffee break
11:00-12:15h Tumor Board: Localised Disease
• Not-so-active surveillance? When to skip biopsy. Which patient suits best?
• Radiotherapy vs. Surgery: Head to head discussion
• Brachytherapy for all of you, low and intermediate risk guys?
• Surgical steps for better oncological and functional outcomes
• The optimal candidate for local treatment
• Radical prostatectomy: Open? Robotic? Lap: Lost in the middle?
• PLND: Big or huge?
• How different is LND in prostate cancer from other pelvic diseases?
• Management of clinically node positive patients
• Positive margins after radical prostatectomy. Now what?
• Focal therapy – Ready for prime time? (Follow-up, complications, redo cases)
• Focal therapy – Are they all alike? (Cryosurgery, brachytherapy, HIFU, irreversible electroporation, interstitial laser and photodynamic therapy) Only experimental?
• How to select patients for good focal treatment (Pre-therapy criteria, energies, etc…)
12:15-12:45h Locally advanced disease
• Is there a role for surgery and salvage lymph node dissection?
• Positive margins after surgery? What do to do?
• Management of lymph node – Positive PCa
• Neoadjuvant systemic therapy in localized PCa – Back in?
• Active surveillance: As the jury returned?
• Management
12:45-13:15h Oligometastatic disease
• What on earth is oligometastatic disease?
• Oligometastatic Disease: Surgery? RT?
• Cytoreductive radical prostatectomy (M1 disease) – Grows or inhibits metastasis?
13:15-14:30h Lunch
14:30-15:00h Recurrent prostate cancer
• Where did it recur to?
• Biochemical and loco-regional recurrence: Now what?
• Brachytherapy boost with adjuvant radiotherapy; Who and when?
• Failure after focal therapy. Is it peanuts?
• Treatment of local recurrent PCa (whole gland cryotherapy, HIFU)
15:00-15:30h Non-metastatic Castration Resistant Prostate Cancer
• nmCRPC and mCRPC: Diagnostic workup
• Non-metastatic prostate cancer: Recent advancements, novel agents
15:30-16:15h Metastatic Hormone Sensitive Prostate Cancer
• Update on trial results and new trends in mHSPC
• Chemo-hormone treatment in mHSPC
• Management of metastatic prostate cancer: Tips and tricks
• The role of bone-protective agents. When, how and which?
• Hormone-naive metastatic disease first: What should I do?
16:15-16:40h Coffee break
16:40-17:40h Metastatic Castration Resistant Prostate Cancer
• It is now not that naïve: Hormone-resistant prostate cancer: What happened, what should I do?
• mCRPC: Which drugs? What sequence?
• Sequencing treatments in mCRPC – Uncharted territory
• Current management of bone-only metastatic prostate cancer
• Non-urological management of CRPC
17:40-18:00h New benchmarks for radical prostatectomy
• Outpatient prostatectomy
• Retzius sparing trans-douglas radical prostatectomy
• LESS for PCa
SATURDAY, 20TH JUNE 2020 Scientific Program
08:00h Opening of registration desk
08:30-09:00h Follow-up: Castrated and non-castrated patients
• Castrated patients: How to follow-up?
• Oncologic, continence, sexual function, bone health, cardiovascular disease, metabolic syndrome
• How to address cancer co-comorbities
09:00-09:30h Management of complications after primary treatment
• Treatment of radiation stricture – The ultimate guide
• Treatment of bladder neck stricture
• Incontinence treatment: New slings? Stick to the old ones?
• ED treatment after RP and RT
• Orgasmic dysfunction after RP, RT and BT
• Treatment of climaturia
09:30-10:45h Hot, Hot, Hot
• Hot Topics ASCO 2020
• Hot Topics EAU 2020
• Hot Topics AUA 2020
• Hot Topics ESMO 2020
• Hot Topics ASTRO and ESTRO 2020
10:45-11:15h Coffee break
11:15-11:45h Not so hot, still interesting
• Testosterone in prostate cancer: Fuel or brake?
• Is the castrate-resistant prostate cancer an oncologist disease?
• Managing of BPH in active surveillance patients
• PET-PSMA vs. scintigraphy: Is my algorithm all messed up?
• Circulating Tumor cells – What does it mean and how long to be using it in our clinic
• Is there a role for social media in prostate cancer? (Movember 2019? P-Race 2019?)
11:45-12:15h Emerging therapies
• Role of immunotherapy in advanced prostate cancer: Are we there yet
• Role of androgen receptor blockers in advanced prostate cancer
• Role of radiomics on PCa
• Role of PARPs and other novel pathways
• Targeting DNA repair deficiency in PCa
• Role of chemotherapy and radiopharmaceuticals in the management and treatment of advanced prostate cancer
12:15-12:45h Learning and self-assessment
12:45-13:00h Farewell message
Organizing Committee
José Santos DiasSandro GasparTiago OliveiraTomé Lopes
Organization
Secretariat
CMYK0/80/96/0 #5d40322/16/85/0 #fbd14266/79/89/26 #5d4032
Registrations online at www.admedic.pt
Calçada de Arroios, 16 C, Sala 3 1000-027 LisboaT: +351 21 842 97 10E: [email protected]: www.admedic.pt
EARLY FEEUntil December 31st,2019
REGULAR FEEUntil May, 19th, 2020
LATE FEEUntil June 12th,2020
ONSITE
Specialists 400 € 550 € 650 € 750 €
Residents* 250 € 400 € 500 € 550 €
Other healthcare professionals
200 € 300 € 400 € 450 €
*Written confirmation necessary to verify your resident status.
Scientific Committee
Antonio Lopez-Beltran (ES)Karim Touijer (USA)José Santos Dias (PT)Josep Maria Gaya (ES)Miguel Srgougi (BR)Sandro Gaspar (PT)Steven Joniau (BE)Tiago Oliveira (PT)Tomé Lopes (PT)